Daratumumab Intravenous and Lomitapide Mesylate

• Generic Name: daratumumab
• Dosage Forms: n.a.
• Other Brand Names: Darzalex

Daratumumab injection is used alone or together with other medicines to treat multiple myeloma (a type of bone marrow cancer). It is used alone in patients who have received at least 3 prior treatments that did not work well, including a proteasome inhibitor and an immunomodulatory agent, or who did not respond to both a proteasome inhibitor and an immunomodulatory agent.

Daratumumab injection is also used in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, to treat patients with multiple myeloma who have received at least 1 previous treatment.

Daratumumab injection is also used together with bortezomib, melphalan, and prednisone to treat patients with newly diagnosed multiple myeloma who cannot receive autologous stem cell transplant.

Daratumumab injection is also used in combination with pomalidomide and dexamethasone to treat patients with multiple myeloma who have received at least two treatments (including lenalidomide and a proteasome inhibitor).

Daratumumab is to be given only by or under the supervision of your doctor.

• Generic Name: lomitapide
• Dosage Forms: n.a.
• Other Brand Names: Juxtapid

Adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce LDL-cholesterol, total cholesterol, apolipoprotein B (apo B), and non-HDL-cholesterol concentrations in the management of homozygous familial hypercholesterolemia (designated an orphan drug by US FDA for use in this condition).

Safety and efficacy not established in patients with hypercholesterolemia who do not have homozygous familial hypercholesterolemia.

Effects on cardiovascular morbidity and mortality not established.